ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Amphotericin B

Also written as “Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)”, “Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)” and “Amphotericin B Liposome”.

Its studies are mostly in Meningitis, Cryptococcal · Invasive Fungal Infections · Leishmaniasis, Visceral · Aspergillosis · Candidiasis, led by 9 companies.

Drug pageAmphotericin B: every studyMany companies study it; this page follows only the 14 they lead. All 89 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Nov 2, 199914 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only60 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Alkermesits history only10 open or runningphase 1since Nov 2, 1999Nov 2, 1999none ahead
Aurobindo Pharma10 open or runningphase 1since Aug 6, 2018Aug 6, 2018none ahead
Bristol-Myers Squibbits history only10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Johnson & Johnsonits history only10 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Liposomeits history only10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Matinas BioPharma Nanotechnologiesits history only10 open or runningphase 2since Nov 16, 2015Nov 16, 2015none ahead
Merckits history only10 open or runningphase 2since Feb 5, 2004Feb 5, 2004none ahead
Sichuan Huiyu Pharmaceuticalits history only10 open or runningno phasesince Apr 30, 2025Apr 30, 2025none ahead

Also a collaborator on its studies: Axis Clinicals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aurobindo Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2018First study: phase 1 study in Leishmaniasis, VisceralFirst studyNCT03636659 · 140 enrolled · Bangladesh, India

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Ergosterol sequestering agent”ChEMBL 37, by rule

Studies

The one study Aurobindo Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03636659Leishmaniasis, Visceral · Bangladesh, India1CompletedApr 5, 2019140

How it is read

Names in the registry

  • “Amphotericin B”, 11 entries
  • “Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)”, 1 entry
  • “Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)”, 1 entry
  • “Amphotericin B Liposome”, 1 entry
  • “Comparator: amphotericin B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.